バイオ医薬品市場- 世界の産業規模、シェア、動向、機会、予測：製品タイプ別、治療用途別、地域別、競合：2020-2030年

バイオ医薬品の世界市場規模は2024年に4,358億2,000万米ドルとなり、2030年までのCAGRは8.25%で、予測期間中に大きな成長が予測されています。

世界のバイオ医薬品市場は、医薬品・ヘルスケア産業の中でもダイナミックで急速に発展している分野です。同市場は、生物、細胞、タンパク質などの生物学的資源に由来する医薬品や治療法であるバイオ医薬品の開発、生産、商業化を包含しています。これらの製品は、ヘルスケアにおける重要な進歩であり、幅広い疾患や病状に対して高度に的を絞った効果的な治療を提供します。

世界のバイオ医薬品市場は、ここ数年一貫した成長を続けています。この成長の原動力となっているのは、世界人口の高齢化、慢性疾患の増加、ヘルスケア支出の増加、革新的なバイオ医薬品の継続的な導入といった要因です。市場の回復力は景気後退局面でも発揮されており、製薬企業や投資家にとって魅力的な投資機会となっています。

市場促進要因

研究開発イノベーション

主な市場課題

規制上のハードルとコンプライアンスの複雑さ

主な市場動向

バイオテクノロジーの進歩と個別化医療

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のバイオ医薬品市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品タイプ別（モノクローナル抗体、組み換え成長因子、精製タンパク質、組み換えタンパク質、組み換えホルモン、ワクチン、組み換え酵素、細胞および遺伝子治療、合成免疫調節剤、その他）
  • 治療用途別（腫瘍学、炎症性および感染症、自己免疫疾患、代謝疾患、ホルモン疾患、心血管疾患、神経疾患、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米のバイオ医薬品市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のバイオ医薬品市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域のバイオ医薬品市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のバイオ医薬品市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのバイオ医薬品市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界のバイオ医薬品市場：SWOT分析

第14章 競合情勢

• Abbvie Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Johnson & Johnson
• Novartis AG
• Novo Nordisk AS
• Pfizer Inc.
• GlaxoSmithKline PLC
• F. Hoffmann-La Roche AG

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Biopharmaceutical Industry Market was valued at USD 435.82 billion in 2024 and is anticipated to project significant growth in the forecast period with a CAGR of 8.25% through 2030. The Global Biopharmaceutical Industry Market is a dynamic and rapidly evolving sector within the broader pharmaceutical and healthcare industry. It encompasses the development, production, and commercialization of biopharmaceutical products, which are medicinal drugs and therapies derived from biological sources such as living organisms, cells, or proteins. These products represent a significant advancement in healthcare, offering highly targeted and effective treatments for a wide range of diseases and medical conditions.

The global biopharmaceutical market has been on a consistent growth trajectory for several years. This growth is driven by factors such as an aging global population, increasing prevalence of chronic diseases, rising healthcare expenditures, and the continuous introduction of innovative biopharmaceutical products. The market has demonstrated resilience even in the face of economic downturns, making it an attractive investment opportunity for pharmaceutical companies and investors.

Key Market Drivers

Research and Development Innovations

Research and development (R&D) innovations are at the heart of the biopharmaceutical industry. They are essential for the creation of novel therapies, drugs, and treatments. The importance of R&D innovations can be attributed to several factors. For instance, in February 2025, Zydus Lifesciences launched VaxiFlu-4, India's first quadrivalent influenza vaccine, representing a major advancement in vaccine technology. Developed at Zydus's Vaccine Technology Centre in Ahmedabad, it is formulated based on WHO recommendations to protect against emerging influenza virus strains.

With technological breakthroughs such as CRISPR-Cas9 gene editing, next-generation sequencing, and artificial intelligence, scientists can delve deeper into the understanding of diseases and develop innovative solutions. R&D innovations enable biopharmaceutical companies to tackle previously untreatable diseases and medical conditions, addressing unmet healthcare needs. Companies that invest heavily in R&D gain a competitive edge by bringing groundbreaking therapies to market, which can lead to substantial profits and market dominance. Continuous R&D ensures a pipeline of new drugs and therapies, fostering long-term sustainability for the biopharmaceutical industry.

Key Market Challenges

Regulatory Hurdles and Compliance Complexity

The biopharmaceutical industry operates in a highly regulated environment due to the critical nature of healthcare products. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), impose rigorous standards and requirements on the development, testing, and manufacturing of biopharmaceutical products. Meeting these regulatory standards can be a time-consuming and costly process. Companies must invest substantial resources in conducting clinical trials, documenting safety and efficacy data, and ensuring compliance with evolving regulations. Moreover, the variability in regulatory requirements across different countries and regions can pose a significant challenge for global market expansion. Additionally, as biopharmaceutical research advances into newer areas such as gene therapies and cell-based treatments, regulators are often grappling with the development of appropriate guidelines, which can further slowdown product approvals.

Key Market Trends

Biotechnology Advancements and Personalized Medicine

One of the most significant trends in the biopharmaceutical industry is the rapid advancement of biotechnology, particularly in areas like genomics, proteomics, and bioinformatics. These advancements are enabling the development of highly targeted and personalized medicines. Rather than taking a one-size-fits-all approach, biopharmaceutical companies are increasingly tailoring treatments to individual patients based on their genetic makeup, biomarkers, and specific disease characteristics. This trend is transforming the treatment landscape, allowing for more effective therapies with fewer side effects. Personalized medicine not only improves patient outcomes but also reduces healthcare costs by minimizing ineffective treatments and adverse reactions. Biopharmaceutical companies are investing heavily in research to identify biomarkers, develop companion diagnostics, and create therapies that precisely match a patient's genetic profile.

Key Market Players

• Abbvie Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Johnson & Johnson
• Novartis AG
• Novo Nordisk AS
• Pfizer Inc.
• GlaxoSmithKline PLC
• F. Hoffmann-La Roche AG

Report Scope:

In this report, the Global Biopharmaceutical Industry Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biopharmaceutical Industry Market, By Product Type:

• Monoclonal Antibodies
• Recombinant Growth Factors
• Purified Proteins
• Recombinant Proteins
• Recombinant Hormones
• Vaccines
• Recombinant Enzymes
• Cell and Gene Therapies
• Synthetic Immunomodulators
• Others

Biopharmaceutical Industry Market, By Therapeutic Application:

• Oncology
• Inflammatory and Infectious Diseases
• Autoimmune Disorders
• Metabolic Disorders
• Hormonal Disorders
• Cardiovascular Diseases
• Neurological Diseases
• Other

Biopharmaceutical Industry Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Biopharmaceutical Industry Market.

Available Customizations:

Global Biopharmaceutical Industry market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biopharmaceutical Industry Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Monoclonal Antibodies, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Vaccines, Recombinant Enzymes, Cell and Gene Therapies, Synthetic Immunomodulators, Others)
  • 5.2.2. By Therapeutic Application (Oncology, Inflammatory and Infectious Diseases, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders, Cardiovascular Diseases, Neurological Diseases, Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Biopharmaceutical Industry Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Therapeutic Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Biopharmaceutical Industry Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Therapeutic Application
  • 6.3.2. Canada Biopharmaceutical Industry Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Therapeutic Application
  • 6.3.3. Mexico Biopharmaceutical Industry Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Therapeutic Application

7. Europe Biopharmaceutical Industry Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Therapeutic Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Biopharmaceutical Industry Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Therapeutic Application
  • 7.3.2. United Kingdom Biopharmaceutical Industry Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Therapeutic Application
  • 7.3.3. Italy Biopharmaceutical Industry Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Therapeutic Application
  • 7.3.4. France Biopharmaceutical Industry Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Therapeutic Application
  • 7.3.5. Spain Biopharmaceutical Industry Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Therapeutic Application

8. Asia-Pacific Biopharmaceutical Industry Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Therapeutic Application
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Biopharmaceutical Industry Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Therapeutic Application
  • 8.3.2. India Biopharmaceutical Industry Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Therapeutic Application
  • 8.3.3. Japan Biopharmaceutical Industry Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Therapeutic Application
  • 8.3.4. South Korea Biopharmaceutical Industry Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Therapeutic Application
  • 8.3.5. Australia Biopharmaceutical Industry Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Therapeutic Application

9. South America Biopharmaceutical Industry Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Therapeutic Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Biopharmaceutical Industry Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Therapeutic Application
  • 9.3.2. Argentina Biopharmaceutical Industry Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Therapeutic Application
  • 9.3.3. Colombia Biopharmaceutical Industry Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Therapeutic Application

10. Middle East and Africa Biopharmaceutical Industry Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Therapeutic Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Biopharmaceutical Industry Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Therapeutic Application
  • 10.3.2. Saudi Arabia Biopharmaceutical Industry Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Therapeutic Application
  • 10.3.3. UAE Biopharmaceutical Industry Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Therapeutic Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Biopharmaceutical Industry Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Abbvie Inc.
• 14.2. Amgen Inc.
• 14.3. Bristol-Myers Squibb Company
• 14.4. Eli Lilly and Company
• 14.5. Johnson & Johnson
• 14.6. Novartis AG
• 14.7. Novo Nordisk AS
• 14.8. Pfizer Inc.
• 14.9. GlaxoSmithKline PLC
• 14.10. F. Hoffmann-La Roche AG

15. Strategic Recommendations

16. About Us & Disclaimer